Novo Nordisk buys university spinout Ziylo — adding a potential remedy for hypoglycemia to its diabetes pipeline
The busy R&D group at Novo Nordisk is adding an early research program to its arsenal of diabetes therapies.
In a “staged acquisition” that could …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
